Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-04 4:32 pm Purchase | 2025-03-28 | 13G | Sutro Biopharma, Inc. STRO | RA Capital Management, L.P. | 4,434,637 5.300% | 4,434,637 (New Position) | Filing History |
| 2025-03-31 4:57 pm Purchase | 2025-03-27 | 13D | Acumen Pharmaceuticals, Inc. ABOS | RA Capital Management, L.P. | 15,016,063 24.800% | 34,445 (+0.23%) | Filing History |
| 2025-03-31 4:54 pm Purchase | 2025-03-27 | 13D | Tyra Biosciences, Inc. TYRA | RA Capital Management, L.P. | 10,684,890 20.100% | 7,750 (+0.07%) | Filing History |
| 2025-03-17 7:58 pm Purchase | 2025-03-13 | 13D | Mineralys Therapeutics, Inc. MLYS | RA Capital Management, L.P. | 6,287,597 9.900% | 1,338,290 (+27.04%) | Filing History |
| 2025-03-10 4:33 pm Purchase | 2025-03-06 | 13D | Janux Therapeutics, Inc. JANX | RA Capital Management, L.P. | 11,971,377 19.900% | 1,528,196 (+14.63%) | Filing History |
| 2025-03-03 8:17 pm Unchanged | 2025-02-27 | 13D | 89bio, Inc. ETNB | RA Capital Management, L.P. | 20,013,733 13.700% | 0 (Unchanged) | Filing History |
| 2025-02-21 4:15 pm Purchase | 2025-02-19 | 13D | Solid Biosciences Inc. SLDB | RA Capital Management, L.P. | 7,989,820 9.900% | 3,631,342 (+83.32%) | Filing History |
| 2025-02-18 4:25 pm Purchase | 2025-02-10 | 13D | Sionna Therapeutics, Inc. SION | RA Capital Management, L.P. | 10,445,322 23.700% | 10,445,322 (New Position) | Filing History |
| 2025-02-14 6:43 pm Sale | 2024-12-31 | 13G | Verona Pharma plc VRNA | RA Capital Management, L.P. | 7,777,942 8.900% | -682,148 (-8.06%) | Filing History |
| 2025-02-14 6:43 pm Purchase | 2024-12-31 | 13G | Unicycive Therapeutics, Inc. UNCY | RA Capital Management, L.P. | 11,520,120 9.900% | 1,047,745 (+10.00%) | Filing History |
| 2025-02-14 6:42 pm Sale | 2024-12-31 | 13G | Tenaya Therapeutics, Inc. TNYA | RA Capital Management, L.P. | 0 0.000% | -7,980,736 (Position Closed) | Filing History |
| 2025-02-14 6:42 pm Purchase | 2024-12-31 | 13G | NewAmsterdam Pharma Company N.V. NAMS | RA Capital Management, L.P. | 10,875,454 9.900% | 1,779,865 (+19.57%) | Filing History |
| 2025-02-14 6:41 pm Sale | 2024-12-31 | 13G | Recursion Pharmaceuticals, Inc. RXRX | RA Capital Management, L.P. | 7,725,096 2.000% | -7,659,519 (-49.79%) | Filing History |
| 2025-02-14 6:40 pm Purchase | 2024-12-31 | 13G | Protara Therapeutics, Inc. TARA | RA Capital Management, L.P. | 3,431,713 9.900% | 1,358,638 (+65.54%) | Filing History |
| 2025-02-14 6:39 pm Sale | 2024-12-31 | 13G | MacroGenics, Inc. MGNX | RA Capital Management, L.P. | 0 0.000% | -4,053,077 (Position Closed) | Filing History |
| 2025-02-14 6:39 pm Sale | 2024-12-31 | 13G | Longboard Pharmaceuticals, Inc. LBPH | RA Capital Management, L.P. | 0 0.000% | -3,073,119 (Position Closed) | Filing History |
| 2025-02-14 6:38 pm Sale | 2024-12-31 | 13G | GlycoMimetics, Inc. GLYC | RA Capital Management, L.P. | 0 0.000% | -6,383,000 (Position Closed) | Filing History |
| 2025-02-14 6:37 pm Purchase | 2024-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | RA Capital Management, L.P. | 3,181,818 4.700% | 86,682 (+2.80%) | Filing History |
| 2025-02-14 6:36 pm Sale | 2024-12-31 | 13G | Evolent Health, Inc. EVH | RA Capital Management, L.P. | 3,577,197 3.100% | -4,701,906 (-56.79%) | Filing History |
| 2025-02-14 6:34 pm Sale | 2024-12-31 | 13G | Ensysce Biosciences, Inc. ENSC | RA Capital Management, L.P. | 0 0.000% | -98,400 (Position Closed) | Filing History |